NCT07424027 Central Vein Sign in Multiple Sclerosis Extension Study
| NCT ID | NCT07424027 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Cleveland Clinic |
| Condition | Multiple Sclerosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-10-07 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-10-07 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Multiple sclerosis (MS) is a common disease of the central nervous system that affects almost 1 million people in the United States. However, diagnosing MS can be difficult and often leads to misdiagnosis. More sensitive and specific biomarkers are needed to help with the diagnosis, prognosis, and evaluation of treatment response for MS. The central vein sign (CVS) and the paramagnetic rim lesion (PRL) are two biomarkers that have shown promise in improving diagnostic accuracy for MS. The goal of this study is to provide pilot information on the long-term performance of the CVS and PRL to help diagnose and follow people with MS. The study will follow 40 participants over 48 months to determine if the CVS and PRL help make a diagnosis of MS and how they can be used to follow people with MS. The study will also examine how PRL and CVS change over 48 months. The results of this pilot study will inform the development of a grant application to extend 5-year follow-up for all 420 participants of the CAVS-MS study. The study will use high-resolution T2\*-weighted MRI to detect the CVS and PRLs. An MRI of the brain with contrast will be used to examine CVS, PRL and longitudinal analysis of lesions that slowly grow over time (slowly expanding lesions \[SELs\]). The results of this study have the potential to improve the accuracy of diagnosing and treating MS.
Eligibility Criteria
Inclusion Criteria: * Participants must be enrolled in and meet all inclusion criteria of the CAVS-MS study. * Must have participated in the CAVS-MS study and have completed month 24 visits. * Able to provide written informed consent to participate in the study. Exclusion Criteria: * Contraindication to MRI studies; metal or metal implants incompatible with MRI * Inability to tolerate MRI due to claustrophobia or known excessive movement (e.g. tremor).
Contact & Investigator
Daniel Ontaneda, MD, PHD
PRINCIPAL INVESTIGATOR
The Cleveland Clinic
Frequently Asked Questions
Who can join the NCT07424027 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07424027 currently recruiting?
Yes, NCT07424027 is actively recruiting participants. Contact the research team at kilbanm@ccf.org for enrollment information.
Where is the NCT07424027 trial being conducted?
This trial is being conducted at Los Angeles, United States, Cleveland, United States, Philadelphia, United States.
Who is sponsoring the NCT07424027 clinical trial?
NCT07424027 is sponsored by The Cleveland Clinic. The principal investigator is Daniel Ontaneda, MD, PHD at The Cleveland Clinic. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.